Three experts resign as FDA advisors over approval of Alzheimer?s drug

Fallout continues from the Food and Drug Administration’s contentious decision this week to approve Biogen’s Alzheimer’s drug Aduhelm (aducanumab) despite a lack of efficacy data.Three experts who sat on an advisory committee for the FDA have now resigned over the decision.Nevertheless, the FDA approved the drug on Monday. In a searing resignation letter sent to acting FDA Commissioner Janet Woodcock on Thursday, Kesselheim called the FDA’s decision "probably the worst drug approval decision in recent US history."He noted that the surrogate endpoint was not discussed by the advisory committee—in fact, he notes, the FDA told the committee specifically that it would not use amyloid beta plaque clearing as a surrogate for efficacy.Kesselheim also criticized other aspects of how the FDA oversaw the committee meeting, writing:At our public meeting, concerns about trial data from one of the FDA’s own reviewers were not given adequate time for discussion, and some of the questions FDA asked the Committee to answer were worded in a way that seemed slanted to yield responses that would favor the drug’s approval.Overall, he described the decision as a debacle and wrote that “it is clear to me that FDA is not presently capable of adequately integrating the Committee's scientific recommendations into its approval decisions." As such, he resigned from the committee, on which he had served since 2015.In resigning, he joins neurologists David Knopman of the Mayo Clinic in Minnesota and Joel Perlmutter of Washington University in St. Louis, both of whom also announced resignations this week.As for the remaining questions about the efficacy of Biogen’s Aduhelm, the FDA required Biogen to conduct another clinical trial to assess the drug’s efficacy.